

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
KBI-0003

Total Pages in this Submission

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application invention entitled:

COMPOSITIONS AND METHODS FOR ALLEVIATING SYMPTOMS OF UREMIA IN PATIENTS

and invented by:

Ranganathan et al.

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 23 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☒ Cross References to Related Applications (if applicable)
 - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. ☐ Reference to Microfiche Appendix (if applicable)
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☐ Brief Description of the Drawings (if drawings filed)
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
KBI-0003

Total Pages in this Submission

Application Elements (Continued)

3. ☐ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☐ Formal b. ☐ Informal Number of Sheets _____
4. ☒ Oath or Declaration
- a. ☒ Newly executed (original or copy) ☐ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche
7. ☐ Genetic Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☒ Assignment Papers (cover sheet & documents)
9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☐ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EL55012853US

UTILITY PATENT APPLICATION TRANSMITTAL (Small Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
KBI-0003

Total Pages in this Submission

Accompanying Application Parts (Continued)

15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Small Entity Statement(s) - Specify Number of Statements Submitted: 1
17. ☐ Additional Enclosures (please identify below):

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	7	- 20 =	0	x \$9.00	\$0.00
Indep. Claims	2	- 3 =	0	x \$39.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$345.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$345.00

- ☒ A check in the amount of \$345.00 to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 12-1086 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: April 20, 2000

Jane Massey Licata

Signature

Jane Massey Licata
Reg. No. 32,257
Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, NJ 08053
Tel: 856-810-1515
Fax: 856-810-1454

CC:

KBI-0003

CERTIFICATE OF EXPRESS MAILING

"Express Mail" Label No.EL550125533US

Date of Deposit APRIL 20, 2000

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the "BOX Patent Application", Assistant Commissioner for Patents, Washington, D.C. 20231.

- 1) Patent Application Transmittal Letter (2 copies);
- 2) Application consisting of 23 pages of Specification, including one (1) page of Claims, and one (1) page of Abstract;
- 3) Return Post Card;
- 4) Check in the amount of \$345.00;
- 5) Verified Statement Claiming Small Entity Status;
- 6) Executed Declaration and Power of Attorney; and
- 7) Executed Assignment with Recordation Form (in duplicate).

Jane Massey Licata
JANE MASSEY LICATA

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27 (c)) - SMALL BUSINESS CONCERN**

Docket No.
KBI-0003

Serial No.
Not yet assigned

Filing Date
Herewith

Patent No.

Issue Date

Applicant/ **Ranganathan et al.**
Patentee:

Invention: **COMPOSITIONS AND METHODS FOR ALLEVIATING SYMPTOMS OF UREMIA IN PATIENTS**

I hereby declare that I am:

- ☐ the owner of the small business concern identified below:
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: **Kibow Biotech, Inc.**

ADDRESS OF CONCERN: **Philadelphia, PA**

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the above identified invention described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern or organization exists.
☐ each such person, concern or organization is listed below.

FULL NAME _____

ADDRESS _____

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME _____

ADDRESS _____

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME _____

ADDRESS _____

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME _____

ADDRESS _____

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

Natarajan Ranganathan

TITLE OF PERSON SIGNING

OTHER THAN OWNER:

Sr. Vice President of Research & Development and Operations

ADDRESS OF PERSON SIGNING:

University City Science Center3624 Market Street, One EastPhiladelphia, PA 19104

SIGNATURE:

Natarajan Ranganathan

DATE:

4/19/2000

COMPOSITIONS AND METHODS FOR ALLEVIATING SYMPTOMS OF UREMIA
IN PATIENTS

Introduction

This application claims the benefit of provisional U.S.
5 Application Serial No. 60/131,774, filed April 30, 1999.

Background of the Invention

Kidney disease is ranked fourth among the major diseases
in the United States afflicting over 20 million Americans.
More than 90,000 patients die each year because of kidney
10 diseases. In recent years the number of chronic kidney
failure patients has increased about 11 percent annually.
About 80,000 Americans on dialysis die of various
complications each year and more than 27,000 are on waiting
lists for kidney transplants each year with only about 11,000
15 of these patients receiving transplants.

Nearly 250,000 Americans suffer from end stage renal
disease (ESRD), which is the final stage in chronic renal
failure. Currently hemo- or peritoneal- dialysis and renal
transplant are the only treatment modalities. However, the
20 economic costs of these treatment modalities is extremely
high. For example, in 1996 in the United States alone, the
annual cost of ESRD treatment was over 14 billion dollars.
In developing and underdeveloped countries with low health
care budgets, ESRD patients are deprived access to such
25 treatments due to their high costs. Accordingly, there is a
need for alternative modalities of treatment for uremia.

A number of treatment attempts have been based on the
use of the bowel as a substitute for kidney function. During
a normal digestive process the gastrointestinal tract delivers
30 nutrients and water to the bloodstream and eliminates waste

products and undigested materials through the bowel. The intestinal wall regulates absorption of nutrients, electrolytes, water and certain digestive aiding substances such as bile acids. The intestinal wall also acts as a semi-permeable membrane allowing small molecules to pass from the intestinal tract into the bloodstream and preventing larger molecules from entering the circulation.

Nitrogenous wastes such as urea, creatinine and uric acid, along with several other small and medium molecular weight compounds, flow into the small intestine and equilibrate across the small intestine epithelium. Studies of intestinal dialysis have shown a daily flow of 71 grams of urea, 2.9 grams of creatinine, 2.5 grams of uric acid and 2.0 grams of phosphate into the intestinal fluid (Sparks, R.E. *Kidney Int. Suppl.* 1975 Suppl 3, 7:373-376). Accordingly, various invasive and noninvasive attempts including external gut fistula, intestinal dialysis, induced diarrhea, and administration of oral sorbents and/or encapsulated urease enzyme have been made to extract uremic waste from the gastrointestinal tract (Twiss, E.E. and Kolff, W.J. *JAMA* 1951 146:1019-1022; Clark et al. *Trans. Am. Soc. Artif. Intern. Organs* 1962 8:246-251; Pateras et al. *Trans. Am. Soc. Artif. Intern. Organs* 1965 11:292-295; Shimizu et al. *Chemical Abstracts* 1955 103:129004; Kjellstrand et al. *Trans. Am. Soc. Artif. Intern. Organs* 1981 27:24-29; and Kolff, W.J. *Kidney Int.* 1976 10:S211-S214).

Activated charcoal was the first oral sorbent studied for treatment of uremia. Activated charcoal is a highly porous material with large surface area obtained by carbonization of organic materials such as wood, petroleum, coal, peat, and coconut shell followed by activation with steam, carbon dioxide or chemicals such as zinc chloride. Solute adsorption by activated charcoal depends on a number of factors including concentration of the solute in bulk

phase, chemical nature of the solute, temperature, and pH. In general, however, activated charcoal binds more avidly to non-polar solutes than polar solutes. In *in vivo* studies, 190 grams of activated charcoal was required to remove 450 mg of creatinine (Goldenhersh et al. *Kidney Int.* 1976 10:S251-S253). This reduced efficacy is believed to be due to adsorption of other lipophilic compounds such as cholesterol and related bile acids (Kolff, W.J. *Kidney Int.* 1976 10:S211-S214; Goldenhersh et al. *Kidney Int.* 1976 10:S251-S253).

10 Microencapsulation of activated charcoal has been shown to reduce the amount of charcoal needed to 50 grams (Goldenhersh et al. *Kidney Int.* 1976 10:S251-S253).

AST-120, a proprietary and specially-prepared, coated material of porous carbon of 0.2 to 0.4 mm, has been demonstrated to be a more effective charcoal based adsorbent. A dose of 3.2 to 7.2 grams to uremic patients has been disclosed to delay the rise in serum level of creatinine and delay the onset of renal dysfunction in nephrectomized rats as well as 27 uremic patients (Owadu, A. and Shiigai, T. *Am. J. Nephrol.* 1996 16(2):124-7; and Okada, K. and Takahashi, S. *Nephrol. Dial. Transplant.* 1995 10(5):671-6).

Several studies have also shown that ingestion of dialdehyde starch, also referred to as oxystarch, resulted in increased excretion of non-protein nitrogen (Giordano et al. *Bull. Soc. Ital. Biol. Sper.* 1968 44:2232-2234; Giordano et al. *Kidney Int.* 1976 10:S266-S268; Friedman et al. *Proc. Clin. Dia. Trans. Forum* 1977 7:183-184). Unlike activated charcoal where adsorption of the uremic solute is a physical process easily reversible, dialdehyde starch binds urea and ammonia via chemisorption involving covalent binding to the two-aldehyde groups. However, like activated charcoal, ingestion of very large amounts of about 30-50 grams only removed 1.5 grams of urea. Additional studies wherein dialdehyde starch and activated charcoal were both ingested demonstrated some

improvement in uremic waste removal (Friedman et al. *Proc. Clin. Dia. Trans. Forum* 1977 7:183-184). Further, coating of dialdehyde starch with gelatin and albumin resulted in 6-fold better sorbency as compared to uncoated dialdehyde starch
5 (Shimizu et al. *Chemical Abstracts* 1982 97:222903). More recently, retardation of progression of chronic renal failure has been shown following administration of chitosan coated oxycellulose or cellulose dialdehyde (Nagano et al. *Medline Abstract UI* 96058336 1995).

10 Locust bean gum, a naturally available carbohydrate based polymeric oral sorbent, when administered at 25 grams/day in cottonseed oil to uremic patients, was also demonstrated to remove significant amounts of urea, creatinine and phosphate. Further, locust bean gum adsorbs about 10 times
15 its own weight in water (Yatzidis et al. *Clinical Nephrology* 1979 11:105-106).

Dietary supplementation with gum arabic fiber has also been demonstrated to increase fecal nitrogen excretion and lower serum nitrogen concentration in chronic renal failure
20 patients on low protein diets (Bliss et al. *Am. J. Clin. Nutr.* 1996 63:392-98).

Encapsulated urease enzyme has also been investigated as a nonabsorbable oral sorbent for binding ammonia. In early studies zirconium phosphate and encapsulated urease enzyme
25 were used as a non-absorbable oral sorbent for binding ammonia (Kjellstrand et al. *Trans. Am. Soc. Artif. Intern. Organs* 1981 27:24-29). A liquid-membrane capsule device with encapsulated urease to hydrolyze urea to ammonia and citric acid to neutralize the ammonia has also been investigated (Asher et
30 al. *Kidney Int.* 1976 10:S254-S258). Soil bacteria has also been used to recycle urea as metabolically useful amino acids (Setala, K. *Kidney Intl Suppl.* 1978 8:S194-202). In addition, genetically engineered *E. herbicola* cells have been encapsulated and demonstrated to convert ammonia into usable

amino acids for the cells before being eliminated via the bowel. Microencapsulated genetically engineered *E. coli* DH5 cells have also been shown to be effective in removal of urea and ammonia in an *in vitro* system and in a uremic rat animal
5 model (Prakash, S. and Chang, T.M.S. *Biotechnology and Bioengineering* 1995 46:621-26; and Prakash, S. and Chang, T.M.S. *Nature Med.* 1996 2:883-887).

For effective treatment of renal failure, however, it has been estimated that at least 6.0 grams of urea, 0.5 grams
10 of creatinine, 0.5 grams of uric acid and 1.2 grams of phosphate must be removed. Accordingly, there is a need for more effective treatments which remove multiple uremic toxins at higher concentrations to alleviate the symptoms of uremia in patients.

15 The present invention relates to compositions and methods of using these compositions to alleviate the symptoms of uremia. Compositions of the present invention comprise a mixture of sorbents with specific adsorption affinities for uremic toxins such as ammonia, urea, creatinine, phenols,
20 indoles, and middle molecular weight molecules. These compositions also comprise a bacterial source which metabolizes urea and ammonia. These compositions are microencapsulated and/or enteric coated to deliver the sorbent and bacterial source to the ileal and colonic regions wherein
25 maximal resorption of uremic solutes and other molecules occurs.

Summary of the Invention

An object of the present invention is to provide
30 microencapsulated and/or enteric coated compositions which comprise a mixture of sorbents with specific adsorption affinities for uremic toxins including ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules; and a bacterial source which metabolizes urea and

ammonia for use in patients in the alleviation of symptoms associated with uremia.

Another object of the present invention is to provide a method of alleviating symptoms of uremia in a patient which
5 comprises administering orally to a patient suffering from uremia a microencapsulated and/or enteric coated composition comprising a mixture of sorbents with specific adsorption affinities for uremic toxins including ammonia, urea, creatinine, phenols, indoles, and middle molecules; and a
10 bacterial source which metabolizes urea and ammonia.

Detailed Description of the Invention

In kidney failure there is a decrease in the glomerular filtration rate and the kidneys are unable to maintain homeostasis of the blood. Homeostatic balance of water,
15 sodium, potassium, calcium and other salts is no longer possible and nitrogenous wastes are not excreted. Retention of water causes edema and as the concentration of hydrogen ions increases, acidosis develops. Nitrogenous wastes accumulate and a condition referred to as uremia develops in
20 the blood and tissue. Uremic toxins can be defined as solutes that: (I) are normally excreted by healthy kidneys, (ii) accumulate progressively during the development of renal failure so that their concentration increases, and (iii) inhibit various physiologic and biochemical functions; as a
25 whole, they contribute to a complex set of clinical symptoms that comprise the Uremic Syndrome. Examples of uremic toxins include, but are not limited to, ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules. More specifically, in uremia, the concentration of serum
30 creatinine, blood urea nitrogen (BUN), uric acid, and guanidino compounds such as N-methyl guanidine (NMG) and guanidino succinic acid (GSA) are significantly altered with accompanying abnormalities in acid-base equilibrium, electrolytes and water retention. In addition, there are .

several known and unknown substances of low and middle molecular weight which have been identified as uremic toxins which also accumulate. If untreated the acidosis and uremia can cause coma and eventually death.

- 5 Further, as a result of poor clearance of waste products of metabolism, there are some compensatory as well as adaptive processes, which further complicate the condition. For example, bacterial overgrowth of the normal flora of the gut occurs when kidney function is reduced to less than 20% and
- 10 creatinine levels in the serum increase to 8 mg/dl. Substantially increased metabolism of normal substrates and a large variety of toxic amines, such as methylamine, dimethylamine, trimethylamine, phenols and indole metabolites also occurs from this bacterial outgrowth. When the small gut
- 15 bacterial growth increases, there is an increase in ammonia release which then enters the enterohepatic circulation and is converted to urea.

- The introduction of renal dialysis has contributed to rapid progress in the clinical treatment of renal failure and
- 20 elucidation of uremia. When a patient has mild kidney failure where the serum creatinine level is less than 400 $\mu\text{mol/L}$, the patient does not require renal replacement therapy such as dialysis or renal transplant. However, in general, when the serum creatinine level rises to 900 $\mu\text{mol/L}$, the patient needs
- 25 routine dialysis or a kidney transplant to survive.

- Dialysis can serve as a lifetime therapy for ESRD patients. Phosphate binders such as calcium acetate, calcium carbonate or aluminum hydroxide are generally prescribed for uremic patients receiving dialysis to reduce elevated
- 30 phosphate levels. In general, however, dialysis is very expensive, inconvenient, time consuming and may occasionally produce one or more side effects. With a successful kidney transplant, a patient can live a more normal life with less long-term expense. However, there are also high costs
- 35 associated with transplant surgery, the recovery period and .

the continuous need for antirejection medications. Further, there is oftentimes a shortage of suitable donors. Accordingly there is a need for alternative strategies.

- In the present invention, compositions are provided
- 5 which comprise a mixture of sorbents selected for their specific adsorption affinities for uremic toxins such as ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules. For example, in a preferred embodiment, the mixture of sorbents comprises: oxystarch or
- 10 oxycellulose with a specific adsorption affinity for urea and ammonia; locust bean gum with a specific adsorption affinity for creatinine and urea; and activated charcoal with a specific adsorption affinity for creatinine guanidines, phenol, Indican and middle molecular weight undefined
- 15 components. Compositions of the present invention further comprise a bacterial source which metabolizes urea and ammonia, preferably to amino acids which can be used by the bacteria or the patient. Examples of bacterial sources useful in the present invention include, but are not limited, *E. coli*
- 20 DH5, *Sprosarцина urae* and genetically modified yeast cells such as *S. pombe*. The composition is then enteric coated and/or microencapsulated. Enteric coating of the composition is specifically designed to deliver the sorbents and bacterial source at the ileal and colonic regions of the bowel where
- 25 maximal resorption of uremic solutes and other molecules are found to occur. This is preferably achieved via an enteric coating material which disintegrates and dissolves at a pH of 7.5 or higher. Examples of enteric coatings with these characteristics include, but are not limited to, Zein,
- 30 polyglycolactic acid, polylactic acid, polylactide-co-glycolide and similar coating materials. Enteric coatings also enable delivery of the sorbents to their site of action in relatively native form without binding of various digestive materials to the sorbents prior to reaching the target region.
- 35 Alternatively, or in addition, the compositions of the present

invention can be microencapsulated thus permitting the compositions to perform like microscopic dialysis units as described by Chang, T.M.S. (Artificial Cells, Chapter 5, in Biomedical Applications of Microencapsulation, edited by Lim, F. CRC Press Florida, pp 86-100). In this embodiment, the composition is coated with a non-absorbable polymeric compound which permits only small and middle-sized molecules into the core wherein the mixture of solvent and bacterial source are located. Examples of non-absorbable polymeric coatings for microencapsulation include, but are not limited to, alginate/alginate acid, chitosan, cellulose acetate phthalate, hydroxyethyl cellulose and similar coating materials. Microencapsulation prevents the binding of macromolecules and other digestive materials which substantially reduce the efficacy of the sorbents to specifically adsorb the uremic solutes to the sorbents of the mixture. The microcapsules pass through the bowel, with the mixture of sorbents adsorbing multiple uremic solutes and the bacterial source metabolizing urea and ammonia and urea, and are then excreted intact from the bowel. Thus, in this embodiment, the patient is protected from the possibility of microbial infection by the bacterial source as the bacterial source is kept within the microcapsule. Accordingly, in a preferred embodiment, compositions of the present invention are both microencapsulated and enteric coated.

Compositions of the present invention may further comprise a phosphate binding agent such as aluminium hydroxide, calcium carbonate or calcium acetate and a water binding agent such as psyllium fibers, naturally occurring gums or modified starches.

Compositions of the present invention are administered orally to patients with uremia to alleviate the symptoms of uremia. By "alleviation of symptoms" of uremia, it is meant that the composition removes sufficient levels of uremic toxins such that a patient suffering from uremia either does

not require dialysis, requires dialysis less frequently or for shorter durations, or does not require initiation of dialysis as soon.

In a preferred embodiment, oral delivery of the mixture of sorbents in the composition will be accomplished via a 2 to 4 ounce emulsion or paste mixed with an easy to eat food such as a milk shake or yogurt. The microencapsulated bacterial source can be administered along with the mixture of sorbents in the emulsion or paste or separately in a swallowable gelatin capsule.

A mathematical model of solute transport of oral sorbents has been developed based on the diffusion controlled solute flux into the intestinal lumen followed by physical binding or chemical trapping (Gotch et al. *Journal of Dialysis* 1976-1977 1(2):105-144). This model provides the theoretical basis of solute removal through the gut.

For example, gut clearance of urea is 10 to 12 ml/minute in normal renal function and is reduced to 3 to 4 ml/minute in patients with severely reduced renal function. This reduction in the clearance rate is independent of blood urea concentration and directly related to impaired renal function. The normal creatinine clearance rate is 2 to 5 ml/minute.

Further, at steady state, as rate of mass generation is equal to rate of mass elimination, the first order sorbent promoted gut clearance of any solute is given by the mass balance equation:

$$G_s = (K_r + K_g) C_s,$$

where G_s = rate of solute generated, K_r = rate of renal clearance, K_g = rate of gut clearance and C_s is concentration of solute.

The process of sorbent binding, for a given amount of sorbent, is saturable. Thus, below the saturation levels, as the rate of gut clearance of the solute is first order, the above equation can be depicted as:

$$C_s = G_s / (K_r + K_g).$$

Above the saturation levels, as the rate of gut clearance is zero, the equation can be rewritten as:

$$C_s = (G_s - \text{sorbent capacity})/K_r.$$

These equations are useful in predicting the efficacy of
5 solute removal from the gut based *in vitro* studies.

In fact, this model was applied to Friedman's data on urea elimination by the gut in uremic patients using oxystarch oral sorbent (Friedman et al. *Trans. Am. Soc. Artif. Intern. Organs* 1974 20:161-167). With these data, the model showed
10 that maximum sorbent capacity for native oxystarch oral sorbent was 1.5 g/day which is insufficient to replace dialysis or reduce the frequency of dialysis. This model also predicted that for the same patient data, at a protein catabolic rate of 0.95 grams/kg/24 hours and a urea generation
15 of 5 mg/minute, the maximum sorbent capacity of oxystarch should be 7.2 grams of urea nitrogen/day and the gut clearance rate should be 5.6 ml/minute. Sorbent capacity lower than this, such as 5.4 grams of urea/day will at best delay dialysis by months provided the protein catabolic rate can be
20 held at 0.6 grams/kg/24 hours. Thus, this model is useful in determining optimal results for various formulations of compositions of the present invention to alleviate symptoms of uremia in patients.

The following nonlimiting examples are provided to
25 further illustrate the present invention.

EXAMPLES

Example 1: Source of sorbents

Oxystarch (dialdehyde starch) was purchased from MPD-Labs, Feasterville, PA. This is a pharmaceutical grade
30 material (98% pure) with a moisture content of 13% and possessing a minimum 90% oxidized material as per the certificate of analysis by the supplier.

Locust bean gum (minimum 99% pure) was purchased from Sigma-Aldrich, St. Louis, MO.

Activated charcoal, Supra A, pharmaceutical grade (99.9% purity) was purchased from Norit Corporation of America, Atlanta, GA.

Each sorbent material was enteric coated with Zein; 5 microencapsulated with ethocel; and microencapsulated with ethocel and then enteric coated with Zein as the shell materials. Encapsulation runs were performed using a disk process. Three separate shell material solutions were prepared: ethocel alone, Zein alone, and Zein in combination 10 with ethocel. After the shell materials were prepared, each sorbent was added to the shell solution (to provide 60% theoretical payload) and mixed to form a dispersion. The dispersion was then sonicated and pumped at approximately 50 grams/minute onto a disk rotating at approximately 20,000 RPM 15 to create microspheres. The microspheres were formed in a heated cone with an inside temperature of approximately 50°C to evaporate the ethanol and water. The capsules were collected via a cyclone. The native particle size and the particle size after various encapsulations of these sorbents 20 are depicted in Table 1.

Table 1: Encapsulation Formulations

Run Number	Sample Number	Sorbent	Shell System	Initial Particle Size (μm)	Encapsulated Particle Size (μm)
1	19-011	Dialdehyde Starch	10% Ethocel 90% Ethanol	Average: 20	10-100 Average:60
2	19-012	Dialdehyde Starch	15% Zein 76% Ethanol 9% Water	Average: 20	5-80 Average:30
3	19-013	Dialdehyde Starch	7.7% Zein 4.9% Ethocel 83% Ethanol 4.4% Water	Average: 20	10-100 Average:50
4	19-014	Locust Bean Gum	10% Ethocel 90% Ethanol	Average: 100	10-120 Average:50
5	19-015	Locust Bean Gum	15% Zein 76% Ethanol 9% Water	Average: 100	10-200 Average: 30

	6	19-016	Locust Bean Gum	12.3% Zein 8% Ethocel 68% Ethanol 11.7% Water	Average: 100	30-200 Average: 70
	7	19-017	Activated Charcoal	10% Ethocel 90% Ethanol	Average: 5	20-200 Average: 50
	8	19-018	Activated Charcoal	15% Zein 76% Ethanol 9% Water	Average: 5	20-200 Average: 50
	9	19-019	Activated Charcoal	12.3% Zein 8% Ethocel 68% Ethanol 11.7% Water	Average: 5	20-200 Average: 50
5	10	19-020	Aluminium Hydroxide	10% Ethocel 90% Ethanol	Average: 20	10-100 Average: 75
	11	19-021	Aluminium Hydroxide	15% Zein 76% Ethanol 9% Water	Average: 20	10-500 Average: 300 needle-like
	12	19-022	Aluminium Hydroxide	12.3% Zein 8% Ethocel 68% Ethanol 11.7% Water	Average: 20	10-100 Average: 75
	13	19-023	Aluminium Hydroxide	12% Zein 79% Ethanol 9% Water	Average: 20	10-100 Average: 50

Scanning electron micrographs (SEMs) of the raw materials including dialdehyde starch, locust bean gum, activated charcoal and aluminium hydroxide and the twelve microencapsulation formulations were also prepared. Run 11, produced rod-like capsules which was caused by the material not being fed directly into the center of the disk or by the solids content being too high. Run 11 was thus repeated as run 13 with the Zein decreased from 15% to 12% and was successful.

In addition to the SEMs of each run, digital photomicrographs were also taken.

20 **Example 2: E. coli DH5 cells**

Genetically engineered E. coli DH5 cells are obtained from Organica Inc. Valley Forge, PA. The cells are seed cultured, grown, harvested and microencapsulated in accordance with procedures described by Chang and Prakash (*Biotechnology and Bioengineering* 1995 46:621-26).

Example 3: Formulations

Relative *in vitro* efficacy of oxystarch, locust bean gum and activated charcoal in native (N), enteric coated (E), microencapsulated (M), and microencapsulated with enteric coating (ME) alone and in various combinations as shown in Table 2 is assessed.

Table 2: Sorbent Efficacy Determinations

Formulation Number	Amount of Oxystarch (g)	Amount of Locust Bean Gum (g)	Amount of Activated Charcoal (g)
10	1	0	15
	2	0	10
	3	0	5
	4	0	0
	5	5	10
15	6	5	5
	7	5	0
	8	10	0
	9	10	0
20	10	15	0

As shown in Table 2, a three level three variable factorial formulation design is used with the constraint that sum total of the ingredients is constant at 15 grams. This design permits evaluation of individual sorbents (formulation numbers 1, 4 and 10), binary combinations (formulation numbers 2, 3, 6, 7, 8 and 9) and a single ternary 1:1:1 combination of sorbents (formulation number 5).

The efficacy of various concentrations of *E. coli* DH5 cells (5, 10 and 15 grams) in native form and APA (alginic acid-polyglycolide-alginate) microencapsulated form is then assessed.

Efficacy determinations are also made on formulations as depicted in Table 3 containing both sorbents and *E. coli* DH5.

Table 3: Formulation of sorbents plus *E. coli* DH5 efficacy determinations

Formulation Number	Oxystarch (g)	Locust Bean Gum (g)	Activated Charcoal (g)	APA <i>E. coli</i> DH5 cells (g)
1	5	5	5	5
2	5	5	5	10
3	5	5	5	15
4	5	5	10	5
5	5	5	15	5
6	5	10	5	5
7	5	15	5	5
8	10	5	5	5
9	15	5	5	5

As shown in Table 3, a three level four variable factorial design is used to evaluate the addition of APA-microencapsulated *E. coli* DH5 cells with constraints that the amount of each ingredient not exceed 15 grams and the maximum amount of the total formulation not exceed 25 grams.

From the experimental observations and determinations of Table 2, only those specific modified forms demonstrating highest sorbent efficacy both independently and in binary combination will be used in these formulations studies with APA microencapsulated *E. coli* DH5 cells.

A sorbent coating (E, M or ME) will then be selected for ternary sorbent formulation and integration with microencapsulated *E. coli* DH5 cells.

Example 4: *In vitro* efficacy evaluations

A simulated gastric fluid composed of NaCl, HCl and pepsin in distilled water and adjusted to pH 1.2 is prepared.

according to U.S. Pharmacopeia procedures for stability testing of formulations under acidic pH and gastric conditions. Every modified sorbent material, and binary and ternary formulation is tested by stirring a quantity of
5 approximately 5 grams into a test solution of simulated gastric juice at 37°C for 1 to 2 hours to ascertain the integrity of the modified sorbent.

A simulated synthetic intestinal fluid, composed of monobasic potassium hydrogen phosphate, sodium hydroxide,
10 pancreatin mix and distilled water, is also prepared and adjusted to pH 7.5 according to the test solution preparations in U.S. Pharmacopeia. The intestinal fluid is fortified with uremic solutes to make a solution of 150 milligrams of urea, 30 milligrams of creatinine, and 30 milligrams of uric acid
15 per 100 milliliters of synthetic intestinal fluid.

To vary the concentrations, this stock solution is diluted with non-fortified intestinal stock solution to make 75% and 50% concentrations of variable uremic intestinal fluid solutions. Initially 100%, 75% and 50% concentration uremic
20 intestinal fluid solutions are evaluated with a 15 gram sorbent formulation containing 5 grams each of oxystarch, locust bean gum and activated charcoal. From these data, various experimental parameters including, but not limited to volume, concentration of uremic intestinal fluid, and time of
25 pre- and post-treatment can be optimized. Optimal parameters are then used for all additional sorbent evaluations, formulations and experimental determinations. All experimental observations are made in triplicate.

However, initially, sorbent/formulation test runs of 5,
30 10 or 15 grams of sorbent or formulation are treated with 500 ml of fortified intestinal fluid of different concentrations in a graduated measuring cylinder and gently shaken for 8 hours. Samples are drawn from the supernatant at one hour intervals, centrifuged if necessary, and analyzed for urea
35 creatinine and uric acid via commercially available kits.

(Sigma Diagnostics Company, St. Louis, MO). Once the adsorption capacity and equilibration times are determined, this period, estimated to be at least 2 hours, will be used.

All formulations shown in the Tables will then be tested. In these tests, 1.5 grams of sorbent formulation is treated with 50 ml of fortified intestinal fluid in a graduated measuring cylinder. The suspension is gently shaken. A sample is withdrawn every hour and analyzed for urea, creatinine and uric acid. The sediment volume is measured for all time intervals and used to determine the water absorbing capacity of each formulation. A plot of the time versus the amount of solute adsorbed per gram of formulation is also obtained for each formulation and the maximum capacity of sorbent formulation and equilibration time for each formulation is calculated. Identical experiments are performed with unencapsulated and encapsulated *E. coli* DH5 cells to determine urea utilization. Based upon the results of these experiments, five optimized mixtures of modified sorbent formulations with microencapsulated *E. coli* DH5 cells will be selected for studies in the TNO computer controlled Gastro-Intestinal track model, also referred to as the Dutch stomach model, and for studies in animals.

Example 6: TNO Gastro-Intestinal Model (TIM)

The TNO gastro-intestinal model (TIM) simulates very closely the successful dynamic conditions in the lumen of the gastrointestinal track. Dynamic parameters that are simulated include: food and drink intake; the pH curves and the concentrations of enzymes and proenzymes in the stomach including saliva and small intestines including pancreatic juices; the concentration of bile in different parts of the gut; the kinetics passage of chyme through the stomach and small intestines; and the adsorption of water soluble digestive products and water. In the large intestinal model a complex high density microflora of human origin ferments the undigested food compounds in a natural colonic environment.

simulating pH values, absorption of water, and absorption of microbial metabolites such as short chain fatty acids and gas. Accordingly, this model is used to evaluate the fate of various formulations of compositions of the present invention
5 in both the small and large intestines.

Example 7: In vivo studies

Rats weighing approximately 150 \pm 15 grams, with a degree of chronic renal failure (CRF) similar to that found in humans with end-stage renal disease approaching the
10 initiation of dialysis are used to test the effects of orally administered microencapsulated sorbents and *E. coli* DH5 cells at removing uremic toxins that accumulate in CRF and in reducing uremic symptoms. Overall, there are 4 groups including a control group, a group with chronic renal failure
15 and 2 groups with acute renal failure. Specifically, male rats weighing 250-300 grams, approximately 8 weeks in age, are purchased from Charles River or Harlan and housed in cages which prohibit rats from any access to their feces. Baseline measurements of standard clinical chemistries as well as
20 measurements of compounds considered to be uremic toxins are determined for all animals. Rats are then made either acutely uremic or chronically uremic by surgical procedures.

Acute renal failure is produced by bilateral nephrectomy in accordance with procedures described by Waynforth, H.B. and
25 Flecknell, P.A. Nephrectomy. In: Experimental and surgical techniques in the rat. 2nd ed., 1992, Academic Press (Harcourt, Brace, Jovanovich), London, pp. 29, 274-275. After surgery, rats are randomly paired into age or size matched groups and pair fed. Rats are fed by intragastric
30 administration by a curved dosing needle. One group is treated with oral feeding of sorbents along with Kayexylate to control potassium (treated group). The other group receives Kayexylate alone for potassium control only (control group). Both groups are closely monitored for at least 7 to
35 10 days. If sorbents are effective, some prolongation of life

will be observed in the treated groups as compared to the nontreated group.

Chronic renal failure (CRF) is produced by a 2-stage surgical procedure similar to that of the 5/6 nephrectomy
5 model disclosed by Niwa et al. (*Miner. Electr. Metab.* 1997
23:179-184) and Einbacher and Carter (*J. Exp. Med.* 1966
123:239-250) but with some modifications found to give a more profound degree of renal failure similar to people closely
approaching the need for hemodialysis. In this modified
10 procedure, a soft plastic box is sutured around the remnant kidney to prevent excessive hypertrophy following contralateral nephrectomy. This also aids in controlling organ bleeding.

Specifically, a 2 stage approach is used. On the day
15 of the proposed surgery, food is withheld for one hour. The animal is then anesthetized with the inhalation agent, isoflurane (FORANE). The anesthetized rat is placed on its ventral side, left to right of the surgeon. Both flanks are minimally cleaned of fur with an Oster shaver and prepped with
20 Betadine. A sterile field is prepared on the rat's left flank. A dorsoventral incision is made into the abdomen cavity, down the side of the rat near to the costal border of the thorax on the left side. The left kidney is freed of connective tissue and is pulled out gently, preferably by
25 grasping the perirenal fat. The adrenal gland, which is attached loosely to the anterior pole of the kidney by connective tissue and fat, is gently freed by tearing the attachments. The kidney is positioned to have both poles ligated close to the point where the renal artery enters the
30 organ. A loose lasso of new 4.0 monofilament silk is placed around the upper pole and tied tightly taking care not to break the knot. A double reef knot is used. The organ is examined for excessive bleeding. If necessary, diathermy is used to stop oozing and oxycel is used on the cortex. The
35 same procedure is repeated on the lower pole. The remnant

kidney is encased in a pre-made plastic, preferably SARAN wrap, box and secured. The organ is then placed back into the abdomen and the incision closed in 2 layers. The area is swabbed with Betadine and the animal allowed to recover. An
5 analgesic, buprenorphine (0.25 mg/kg) is administered to relieve pain. About 3 to 4 weeks later the right kidney is removed. In this surgery, an abdominal approach is used to permit examination of the remnant kidney. The anesthesia is the same, but a midline incision is made along the linea alba,
10 minimizing bleeding. The bowel is gently moved and the left remnant kidney observed to insure some function. Adjustments to the box are made if necessary. Assuming all is well with the left kidney, the right kidney is exposed and freed from its capsule (leaving the adrenal) and then removed by placing
15 a ligature around the renal blood vessels. Another ligature is placed around the ureter as far from the kidney as possible, towards the midline, but without damaging or occluding any collateral blood vessels that may be encountered. The ligature is tied securely with a double reef
20 knot, and the blood vessels are transected next to the kidney, which is then removed. The incision is closed, an analgesic is given and the animal is permitted to recover in a warm area.

Serum creatinine levels of 2.6 ± 0.2 (range 2.3 to 3.5)
25 and blood urea levels of 98 ± 5 with low morbidity (less than 20% by 4 weeks post-op) have been attained consistently in rats with this modified procedure.

Approximately 5 days after the second surgery, contralateral blood is drawn and rats are matched as closely
30 as possible for weight, serum creatinine and blood urea. They are randomly assigned into a series of 4 groups. Groups A and B are pair fed. Group A consists of CRF rats without any test sorbents. Group B rats receive sorbent. A third group, Group C, is given sorbents and allowed free access to food and
35 water. A comparison between Groups B and C shows the effects

of uremia on appetite and nutrition. A fourth, sham operated group, Group D is used as controls. Rats are observed over a 4 to 7 month period during which they have biweekly blood and urine collected and assayed for dimethyl- and/or trimethyl-amine via gas chromatography as described by Dunn et al. Analytical Chemistry 1976 48:41-44. Animals are also weighed weekly and blood pressure and urine osmalities are measured monthly. They are assessed daily for appetite by following food and water intake. Timed urine collections are also performed monthly and spot urine collected biweekly. Skinfold thickness is also assessed as an additional nutritional measurement. Rats are sacrificed at 7 months and terminal bloods are drawn for clinical chemistries as well as other specific tests. Blood, urine and brain tissue are also assayed for dimethylamine.

For these studies, sorbents are in a suspension form in sterile saline and are administered orally to the rats using a 12 gauge gastric lavage tube.

What is Claimed is:

1. A microencapsulated or enteric coated composition comprising:
 - (a) a mixture of sorbents with specific adsorption
 - 5 affinities for uremic toxins; and
 - (b) a bacterial source which metabolizes urea and ammonia.
2. The composition of claim 1 wherein sorbents of the mixture have specific adsorption affinities for ammonia, urea,
10 creatinine, phenols, indoles, and middle molecular weight molecules.
3. The composition of claim 1 further comprising a phosphate binding agent.
4. The composition of claim 3 further comprising a
15 water binding agent.
5. A method of alleviating symptoms of uremia in a patient suffering from uremia comprising administering orally to a patient suffering from uremia a composition of claim 1.
6. A method of alleviating symptoms of uremia in a
20 patient suffering from uremia comprising administering orally to a patient suffering from uremia a mixture of sorbents with specific adsorption affinities for uremic toxins; and a bacterial source which metabolizes urea and ammonia.
7. The method of claim 6 wherein sorbents of the
25 mixture have specific adsorption affinities for ammonia, urea, creatinine, phenols, indoles, and middle molecular weight molecules.

ABSTRACT

Microencapsulated and/or enteric coated compositions containing a mixture of sorbents with specific adsorption affinities for uremic toxins including ammonia, urea, 5 creatinine, phenols, indoles, and middle molecular weight molecules and a bacterial source which metabolizes urea and ammonia are provided. Also provided are methods of using these compositions to alleviate symptoms of uremia in patients.

Docket No.
KBI-0003

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

COMPOSITIONS AND METHODS FOR ALLEVIATING SYMPTOMS OF UREMIA IN PATIENTS

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____

(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

60/131,774	April 30, 1999
(Application Serial No.)	(Filing Date)
60/131,774	April 30, 1999
(Application Serial No.)	(Filing Date)
60/131,774	April 30, 1999
(Application Serial No.)	(Filing Date)

(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

Form PTO-SB-01 (6-95) (Modified)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Jane Massey Licata, Reg. No. 32,257

Kathleen A. Tyrrell, Reg. No. 38,350

Laura Plunkett, Reg. No. 45,015

of the firm

Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, NJ 08053

Send Correspondence to: Jane Massey Licata
Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, NJ 08053

Direct Telephone Calls to: *(name and telephone number)*
Jane Massey Licata Tel: 856-810-1515

Full name of sole or first inventor Natarajan Ranganathan	4/19/00 Date
Sole or first inventor's signature <i>Natarajan Ranganathan</i>	
Residence Broomall, PA	
Citizenship US citizen	
Post Office Address 10 Colet Circle	
Broomall, PA	

Full name of second inventor, if any Jack Dickstein	
Second inventor's signature <i>Jack Dickstein</i>	4/19/00 Date
Residence Huntingdon Valley, PA	
Citizenship US Citizen	
Post Office Address 318 Keats Road	
Huntingdon Valley, PA	